Helen Collins, M.D.


Dr. Collins joined our Board of Directors in July 2021, with more than 25 years of experience in medical oncology/hematology. Most recently, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics, overseeing the development of bemarituzumab, a first-in-class anti-FGFR2b antibody for the treatment of patients with gastric cancer, until the company’s acquisition by Amgen in April 2021. Previously, Dr. Collins held positions of increasing responsibility at Gilead Sciences, most recently as Program and Clinical Lead for Gilead’s GS-5829 (BET inhibitor) and GS-4059 (BTK inhibitor) programs, and Amgen, most recently as Global Lead of Oncology Biosimilars. Prior to her career in the biopharma industry, Dr. Collins practiced as a medical oncologist/hematologist for 12 years. She earned her M.D. from Johns Hopkins University School of Medicine, completing her residency at Johns Hopkins Hospital and oncology fellowship at Stanford University School of Medicine, and her B.A. from Bryn Mawr College.